|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2020-07-27 |
A Randomized, Open Label, Two Stage, Multicentre, Parallel Group, Multiple Dose, Steady State Study to Compare Bioavailability and Characterize Pharmacokinetic Profile of Test Formulation[Paliperidone Palmitate Extended Release Injectable Suspension By Accord Healthcare,Administered Every Three Months] Relative to Reference Formulation [Invega Trinza®(Paliperidone Palmitate Extended Release Injectable Suspension) By Janssen Pharmaceuticals]and to Establish Bioequivalence in Patients with Schizophrenia Already Receiving A Stable Regimen of Paliperidone Palmitate Extended Release Injectable Suspension.
100 项与 Accord Healthcare, Inc. (Canada) 相关的临床结果
0 项与 Accord Healthcare, Inc. (Canada) 相关的专利(医药)
100 项与 Accord Healthcare, Inc. (Canada) 相关的药物交易
100 项与 Accord Healthcare, Inc. (Canada) 相关的转化医学